Hiroshi Imazeki

P1.084. Exploring the Role of Adjuvant Nivolumab After Neoadjuvant FLOT Followed by Surgery in Resectable ESCC: Implications for Cisplatin-Unfit Patients

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background In Western countries, neoadjuvant chemoradiotherapy (CRT) is standard, and CheckMate 577 showed adjuvant nivolumab prolonged disease free survival (DFS) with non-pathological complete response (non-p...